Session Information
Date: Monday, November 9, 2015
Session Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose:
Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Invasive renal biopsy remains the golden standard for the diagnosis and management of LN. The objective of this study is to validate serum IGFBP-2 as a novel biomarker of LN and to examine if it could reflect renal pathology in LN patients.
Methods:
Serum samples from 85 biopsy-proven lupus nephritis patients, 18 chromic kidney disease (CKD) controls and 20 healthy controls were used for ELISA testing of IGFBP-2 levels.
Results:
Compared to CKD patients of origins other than lupus or healthy controls, serum IGFBP-2 levels were significantly elevated in LN patients. Serum IGFBP-2 levels were able to discriminate LN patients from healthy controls with an Area Under the Curve (AUC) of 0.97 [95% CI: 0.93 to 1.00; P < 0.0001] and CKD disease controls (AUC: 0.65 [95% CI: 0.52 to 0.78; P = 0.043]). In addition, serum IGFBP-2 could serve as a potential indicator of both SLEDAI (active vs. inactive: 448.1 ± 51.9 ng/ml vs. 263.7 ± 41.7 ng/ml; P = 0.009) and rSLEADAI in LN patients (active vs. inactive: 429.1 ± 44.5 ng/ml vs. 213.3 ± 49.1 ng/ml; P = 0.007). Correlation analysis showed a significant correlation between serum IGFBP-2 levels and SLEDAI score (r = 0.379, P < 0.0001, n = 85) as well as rSLEDAI score (r = 0.409, P < 0.0001, n = 85). Serum IGFBP-2 levels also correlated well with serum creatinine levels (r = 0.658, P < 0.001, n = 85), urine protein-to-creatinine levels (r = 0.397, P < 0.001, n = 85), and eGFR levels (r = -0.680, P < 0.001, n = 85). More importantly, in 19 concurrent patients’ samples, serum IGFBP-2 correlate with the chronicity index of concurrent renal pathology (r = 0.576, P = 0.01).
Conclusion:
Serum IGFBP-2 appears to be a promising biomarker for lupus nephritis, reflective of disease activity and chronicity changes in renal pathology.
To cite this abstract in AMA style:
Ding H, Mohan C, Wu T. IGFBP-2 As a Novel Biomarker for Disease Activity and Renal Pathology in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/igfbp-2-as-a-novel-biomarker-for-disease-activity-and-renal-pathology-in-lupus-nephritis/. Accessed July 6, 2020.« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/igfbp-2-as-a-novel-biomarker-for-disease-activity-and-renal-pathology-in-lupus-nephritis/